Stereotactic Hypofractionated Radiation Therapy as a Bridge to Transplantation for Hepatocellular Carcinoma: Clinical Outcome and Pathologic Correlation

Katz, Alan W.; Chawla, Sheema; Qu, Zhenhong; Kashyap, Randeep; Milano, Michael T.; Hezel, Aram F.

doi:10.1016/j.ijrobp.2011.08.032

Cited by 102 publications

(81 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SBRT may help reduce this: following SBRT used as a bridging therapy, 63-100% of patients are reported to proceed to transplant, with low rates of toxicity, and with complete and partial pathological responses reported in 14-29% and 23-64% of lesions respectively [39][40][41][42][43] . Mohamed et al recently compared SBRT, TACE, RFA and yttrium-90 microspheres as bridge to transplant therapies in a retrospective series of 60 patients 43 .…”

Section: Sbrt As a Bridge To Transplantmentioning

confidence: 99%

Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Murray

Dawson

2017

Seminars in Radiation Oncology

View full text Add to dashboard Cite

SBRT is an emerging effective treatment for hepatocellular carcinoma (HCC) associated with acceptable rates of toxicity in appropriately selected patients. Despite often being reserved for patients unsuitable for other local treatments, prospective and retrospective studies have demonstrated excellent long-term control. SBRT may be used as a stand-alone treatment, or as an adjunct to other HCC therapies. Based on available data, SBRT appears to complement existing local liver therapies.Randomised and non-randomized comparative studies are required to better determine the optimal role of SBRT in HCC treatment.

show abstract

Section: Sbrt As a Bridge To Transplantmentioning

confidence: 99%

Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Murray

Dawson

2017

Seminars in Radiation Oncology

View full text Add to dashboard Cite

show abstract

“…Complete necrosis in some of the lesions could be achieved at around 27%. Most of the tumors could be decreased in size or remained stable without dropped off (123).…”

Section: Stereotactic Body Radiotherapy (Sbrt)mentioning

confidence: 98%

“…SBRT had been used as one of the bridging therapies and it was found to be effective, safe with low toxicity profile (122)(123)(124). The dosage given ranged from 40 to 51 Gy.…”

Section: Stereotactic Body Radiotherapy (Sbrt)mentioning

confidence: 99%

Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation

She¹,

Cheung²

2016

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common primary malignancy worldwide especially in the patients with the background of chronic liver disease. Liver transplantation (LT) is the only curative treatment effective for both malignancy as well as the cirrhosis and portal hypertension. Unfortunately, living donor is not always possible and the deceased graft is scarce. Neoadjuvant therapies, therefore, have been developed as a downstaging treatment to try to downstage the tumor within the transplant criteria, or as a bridging therapy to control the tumor growth in patients while waiting in the transplant list. This paper reviewed the common modalities used as bridging and downstaging therapies for patients suffering from HCC before undergoing LT.

show abstract

“…Certain works limit themselves to the RECIST criteria. [18][19][20][21][22] Other publications apply recommended EASL or mRECIST criteria. [23][24][25][26][27] A single article compared the RECIST and EASL criteria in this indication.…”

Section: Evaluation Of Response After Sbrt For Primary Hepatic Tumorsmentioning

confidence: 99%

Evaluation of response after SBRT for liver tumors

Tétreau

Llacer

Riou

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Use of RECIST criteria is also inadequate in the evaluation of response after SBRT for hepatic metastases. Response of liver metastases to SBRT is better assessed with a combination of size and enhancement pattern. The occurrence of a lobulated enhancement during follow up is efficient to predict local progression in a specific, reproducible, and sensitive way. Patients with FDG-avid hepatic metastases are also better evaluated with PET-CT and functional criteria than routine imaging and metric evaluation alone.

show abstract

Stereotactic Hypofractionated Radiation Therapy as a Bridge to Transplantation for Hepatocellular Carcinoma: Clinical Outcome and Pathologic Correlation

Cited by 102 publications

References 26 publications

Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation

Evaluation of response after SBRT for liver tumors

Contact Info

Product

Resources

About